Celldex Therapeutics, Inc.
CLDX
$32.53
$0.531.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -88.54% | -77.98% | -73.94% | -30.25% | 24.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.54% | -77.98% | -73.94% | -30.25% | 24.49% |
| Cost of Revenue | 43.88% | 49.85% | 47.36% | 46.00% | 50.16% |
| Gross Profit | -49.54% | -55.58% | -56.19% | -50.95% | -51.49% |
| SG&A Expenses | 10.44% | 13.72% | 13.59% | 17.70% | 20.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.89% | 42.96% | 40.56% | 40.18% | 43.85% |
| Operating Income | -42.29% | -47.31% | -47.11% | -43.76% | -44.63% |
| Income Before Tax | -58.59% | -63.91% | -45.73% | -32.88% | -23.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.59% | -63.91% | -45.73% | -32.88% | -23.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.59% | -63.91% | -45.73% | -32.88% | -23.45% |
| EBIT | -42.29% | -47.31% | -47.11% | -43.76% | -44.63% |
| EBITDA | -42.89% | -47.99% | -47.82% | -44.45% | -45.42% |
| EPS Basic | -58.13% | -59.30% | -31.70% | -9.70% | 5.14% |
| Normalized Basic EPS | -58.13% | -59.30% | -45.30% | -20.23% | -3.61% |
| EPS Diluted | -58.13% | -59.30% | -31.70% | -9.70% | 5.29% |
| Normalized Diluted EPS | -58.13% | -59.30% | -45.30% | -20.23% | -3.61% |
| Average Basic Shares Outstanding | 0.31% | 3.16% | 9.18% | 18.40% | 29.03% |
| Average Diluted Shares Outstanding | 0.31% | 3.16% | 9.18% | 18.40% | 29.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |